dm+d

Unassigned

New Medicines

RecomodulinSevere sepsis with coagulopathy

Information

Recomodulin
New molecular entity
Asahi Kasei Pharma
Asahi Kasei Pharma

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Recombinant human thrombomodulin
The Surviving Sepsis Campaign (SSC) estimates that the incidence of sepsis is 3 per 1,000 worldwide. Thus the number of cases each year probably reaches 18 million and this, associated with its high mortality rate, makes it a leading cause of death [1].
Severe sepsis with coagulopathy
Intravenous